Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Continued single digit volume growth within the insulin segments globally Slide 28 Fast-acting insulin Segment volume Premix insulin Segment volume NovoRapidⓇ market share NovoMix® market share Long-acting insulin Segment volume TresibaⓇ share - LevemirⓇ share tMU 200 CAGR¹ volume: 5.8% MI penetration: 78.3% 100% tMU 200 CAGR¹ volume: 1.8% MI penetration: 46.3% 100% tMU CAGR¹ volume: 6.7% 100% 200 MI penetration2: 82.7% - 80% 80% 80% 160 160 160 - 60% 60% 60% 120 120 120 +40% 40% 40% 80 80 80 40 + 20% 40 20% 40 20% 0% 0% 0 0% Feb 2013 Feb 2018 Feb 2013 Feb 2018 Feb Feb 2013 2018 1 CAGR for 5-year period. 2 Includes new-generation insulin. tMU: Thousand mega units Note: Modern insulin (MI) penetration is of total segment, ie including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology Source: IQVIA MAT Feb, 2018 volume figures changing diabetes novo nordisk

View entire presentation